title: The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
abstract: OBJECTIVE
  Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis. A weekly dosing regimen of alendronate is preferred by both patients and physicians, as it has the potential to provide greater convenience and enhance compliance. In a 1-yr clinical trial, alendronate (70 mg once weekly) was equally efficacious and at least as well tolerated as the 10-mg daily dose in the treatment of postmenopausal osteoporosis, despite the higher unit dosage required. We conducted a randomized, double blind, placebo- and active-controlled endoscopy study to confirm the results of this clinical trial. We hypothesized that mean endoscopic gastric erosion scores would be similar in subjects receiving alendronate (70 mg once weekly) and those receiving a placebo.
  
  
  METHODS
  Two hundred seventy-seven subjects (90 men and 187 women) were randomized to one of three treatment groups: 1) alendronate (70 mg once weekly) for 10 wk (N = 126), 2) placebo (once weekly) for 10 wk (N = 126), or 3) placebo (once weekly) for 10 wk followed by aspirin (650 mg q.i.d.) for the last week as the positive control (N = 25). Esophagogastroduodenoscopy was performed 5 to 7 days after the last dose of alendronate or matching placebo.
  
  
  RESULTS
  The mean gastric erosion scores (Lanza scale) were similar in subjects given alendronate (70 mg once weekly) and those given a placebo (0.32 vs 0.35, respectively; 95% CI for difference = -0.22-0.16, p = 0.75), whereas scores in both groups were significantly lower than in those given aspirin (3.09; p < 0.001). Endoscopic gastroduodenal ulcers occurred in no alendronate (0%), two placebo (1.7%), and five aspirin (23.8%) subjects. The mean erosion scores in the esophagus and duodenum of alendronate and placebo subjects were also similar. The incidences of upper GI symptoms were similar in the alendronate and placebo subjects and did not suggest a relationship with endoscopic lesions.
  
  
  CONCLUSIONS
  Alendronate (70 mg once weekly) was not associated with any increase in endoscopic lesions in the upper GI tract relative to a placebo.
authors.affiliation: Houston Institute for Clinical Research, Texas 77074, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: Lanza
authors.forename: Bruce
authors.initials: B
authors.lastname: Sahba
authors.forename: Howard
authors.initials: H
authors.lastname: Schwartz
authors.forename: Steven
authors.initials: S
authors.lastname: Winograd
authors.forename: James
authors.initials: J
authors.lastname: Torosis
authors.forename: Hui
authors.initials: H
authors.lastname: Quan
authors.forename: Robert
authors.initials: R
authors.lastname: Reyes
authors.forename: Thomas
authors.initials: T
authors.lastname: Musliner
authors.forename: Anastasia
authors.initials: A
authors.lastname: Daifotis
authors.forename: Albert
authors.initials: A
authors.lastname: Leung
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage*; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy; D012016:Reference Values; D012449:Safety; D012720:Severity of Illness Index; D013272:Stomach Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D019386:Alendronate